Founded in 2020, Singaporean Neuroglee develops customized virtual care programs and digital therapeutics for patients with neurodegenerative diseases. It offers an adaptive learning platform that tracks data from digital biomarkers and uses machine learning to personalize and optimize treatments. In 2021, Neuroglee partnered with The Mayo Clinic (a non-profit, integrated US healthcare provider) to co-develop a remote care program (named as ‘Neuroglee Connect’) to offer remote treatment for patients suffering from mild cognitive impairment (MCI) related conditions. Moreover, its pipeline products include digital therapeutic solutions for Parkinson’s disease and strokes.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.